Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial

被引：0

作者：

Harbeck, Nadia ^{[1
,2
]}

Gluz, Oleg ^{[3
,4
,5
]}

Kuemmel, Sherko ^{[6
,7
]}

Christgen, Matthias ^{[8
]}

Braun, Michael ^{[9
]}

Aktas, Bahriye ^{[10
]}

Luedtke-Heckenkamp, Kerstin ^{[11
]}

Forstbauer, Helmut ^{[12
]}

Grischke, Eva-Maria ^{[13
]}

Schumacher, Claudia ^{[14
]}

Darsow, Maren ^{[15
]}

Krauss, Katja ^{[16
]}

Nuding, Benno ^{[17
]}

Thill, Marc ^{[18
]}

Potenberg, Jochem ^{[19
]}

Uleer, Christoph ^{[20
]}

Warm, Mathias ^{[21
]}

Fischer, Hans H. ^{[22
]}

Malter, Wolfram ^{[23
]}

Hauptmann, Michael ^{[24
]}

Kates, Ronald ^{[4
]}

Graeser, Monika ^{[3
,4
]}

Wuerstlein, Rachel ^{[1
,2
]}

Shak, Steve ^{[25
]}

Baehner, Rick ^{[25
]}

Kreipe, Hans ^{[8
]}

Nitz, Ulrike ^{[3
,4
]}

机构：

[1] LMU Univ Hosp, Dept OB&GYN, Breast Ctr, Munich, Germany

[2] LMU Univ Hosp, CCCLMU, Munich, Germany

[3] Johanniter Bethesda Moenchengladbach, Breast Ctr Niederrhein, Moenchengaldbach, Germany

[4] West German Study Grp, Moenchengaldbach, Germany

[5] Univ Cologne, Moenchengaldbach, Germany

[6] Clin Essen Mitte, Breast Unit, Essen, Germany

[7] West German Study Grp, Essen, Germany

[8] Med Coll Hannover, Inst Pathol, Hannover, Germany

[9] Breast Ctr, Clin Rotkreuz, Munich, Germany

[10] Univ Clin Leipzig, Womens Clin, Leipzig, Germany

[11] Niels Stensen Clin, Clin Oncol, Osnabruck, Germany

[12] Oncol Practice Network Troisdorf, Troisdorf, Germany

[13] Univ Clin Tubingen, Womens Clin, Tubingen, Germany

[14] St Elizabeth Hosp, Cologne, Germany

[15] Luisenhospital Duesseldorf, Practice Senol Oncol, Dusseldorf, Germany

[16] Univ Clin Aachen, Womens Clin, Aachen, Germany

[17] Ev Hosp Bergisch Gladbach, Bergisch Gladbach, Germany

[18] Agaples Markus Hosp, Breast Ctr, Frankfurt, Germany

[19] Ev Waldkrankenhaus Berlin, Berlin, Germany

[20] Gynecologists & Bahnhofspl, Hildesheim, Germany

[21] City Hosp Holweide, Breast Ctr, Cologne, Germany

[22] Evangel Kliniken, Gelsenkirchen, Germany

[23] Univ Clin Cologne, Womens Clin & Breast Ctr, Cologne, Germany

[24] Brandenburg Med Sch Theodor Fontane, Neuruppin, Germany

[25] Genom Hlth Inc, Redwood City, CA USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GS4-04

引用

页数：1

共 24 条

[21] Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2-breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study
Loibl, Sibylle
Hauke, Jan
Gelmon, Karen
Marme, Frederik
Ernst, Corinna
Martin, Miguel
Untch, Michael
Bonnefoi, Herve
Knudsen, Erik
Im, Seock-Ah
DeMichele, Angela
Van't Veer, Laura
Kim, Sung-Bae
Bear, Harry
McCarthy, Nicole
Turner, Nicholas
Witkiewicz, Agnieszka
Rojo, Federico
CANCER RESEARCH, 2022, 82 (04)
[22] Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
Loibl, Sibylle
Marme, Frederik
Martin, Miguel
Untch, Michael
Bonnefoi, Herve
Kim, Sung-Bae
Bear, Harry
Mc Carthy, Nicole
Mele Olive, Mireia
Gelmon, Karen
Garcia Saenz, Jose
Kelly, Catherine M.
Reimer, Toralf
Toi, Masakazu
Rugo, Hope S.
Seiler, Sabine
Nekljudova, Valentina
Denkert, Carsten
Gnant, Michael
Makris, Andreas
Burchardi, Nicole
von Minckwitz, Gunter
CANCER RESEARCH, 2021, 81 (04)
[23] First Results From a Phase 3 Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1 to 3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score <25: SWOG S1007 (RxPONDER)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 6 - 7
[24] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Johnston, Stephen R. D.
Toi, Masakazu
O'Shaughnessy, Joyce
Rastogi, Priya
Campone, Mario
Neven, Patrick
Huang, Chiun-Sheng
Huober, Jens
Jaliffe, Georgina Garnica
Cicin, Irfan
Tolaney, Sara M.
Goetz, Matthew P.
Rugo, Hope S.
Senkus, Elzbieta
Testa, Laura
Del Mastro, Lucia
Shimizu, Chikako
Wei, Ran
Shahir, Ashwin
Munoz, Maria
San Antonio, Belen
Andre, Valerie
Harbeck, Nadia
Martin, Miguel
LANCET ONCOLOGY, 2023, 24 (01): : 77 - 90

← 1 2 3 →

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score &lt;26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial